Rocket Pharma officer plans $256K stock sale

Form 144 for Rocket Pharmaceuticals officer Martin Wilson covers potential resale of vested equity, including shares sold to satisfy tax obligations.

Rhea-AI Filing Summary

ROCKET PHARMACEUTICALS, INC. (RCKT) is the issuer for a planned sale of common stock reported on a Form 144 for the account of officer Martin Wilson. The notice covers up to 75,364 shares of common stock held at Fidelity Brokerage Services LLC, with an estimated aggregate market value of $256,486.30 as of September 11, 2026, based on a market value of $3.40 per share. The securities to be sold arise from restricted stock vesting on September 9, 2026, categorized as compensation. A remark states that the sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution. The filing also lists prior sales of 3,493 and 631 shares of RCKT common stock on August 13, 2026 and August 18, 2026, respectively.

Key Figures

Shares to be sold: 75,364 shares Estimated aggregate market value: $256,486.30 Market value per share: $3.40 per share +4 more

7 metrics

Shares to be sold 75,364 shares Maximum RCKT common shares covered by Form 144 for Martin Wilson

Estimated aggregate market value $256,486.30 Value of 75,364 RCKT shares using $3.40 per share as of September 11, 2026

Market value per share $3.40 per share Estimated market value used in the Form 144 as of September 11, 2026

Vesting date of restricted stock September 9, 2026 Date of restricted stock vesting giving rise to the shares to be sold

Prior sale 1 3,493 shares for $11,810.18 RCKT common stock sold on August 13, 2026

Prior sale 2 631 shares for $2,133.66 RCKT common stock sold on August 18, 2026

Date of notice September 11, 2026 Filing date of the Form 144 notice

Key Terms

Rule 144, Restricted Stock Vesting, attorney-in-fact, vested equity award distribution

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Common | 09/09/2026 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

attorney-in-fact regulatory

"as attorney-in-fact for Martin Wilson"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

vested equity award distribution financial

"resulting from the settlement of a vested equity award distribution."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for ROCKET PHARMACEUTICALS, INC. (RCKT)?

It discloses a proposed sale of up to 75,364 shares of RCKT common stock for officer Martin Wilson under Rule 144, with an estimated aggregate market value of $256,486.30 as of September 11, 2026, and notes earlier sales in August 2026.

How many RCKT shares are covered by this Form 144 notice for Martin Wilson?

The notice covers up to 75,364 shares of Rocket Pharmaceuticals common stock to be sold for the account of officer Martin Wilson, arising from restricted stock vesting on September 9, 2026.

What is the estimated market value of the RCKT shares covered by the Form 144?

The filing lists an estimated aggregate market value of $256,486.30 for the 75,364 shares of RCKT common stock, based on a market value of $3.40 per share as of September 11, 2026.

Why is Martin Wilson selling Rocket Pharmaceuticals (RCKT) shares according to the Form 144?

The remarks state that the sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution related to restricted stock vesting on September 9, 2026.

Were there recent sales of RCKT stock by Martin Wilson before this notice?

Yes. The Form 144 lists prior sales during the past three months: 3,493 shares of RCKT common stock on August 13, 2026 for $11,810.18, and 631 shares on August 18, 2026 for $2,133.66.

Who is executing the planned RCKT share sale for Martin Wilson?

The broker listed is Fidelity Brokerage Services LLC, and the notice is signed by Adam Gehring as a duly authorized representative of Fidelity, acting as attorney-in-fact for Martin Wilson.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 04:57 PM Accepted by SEC EDGAR 09/11/2026 - 04:57 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001704342
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ROCKET PHARMACEUTICALS, INC.
SEC File Number	001-36829
Address of Issuer	350 FIFTH AVENUE SUITE 7530 NEW YORK NEW YORK 10118
Phone	646-440-9100
Name of Person for Whose Account the Securities are To Be Sold	Wilson Martin
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	75364	256486.30	109774597	09/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/09/2026	Restricted Stock Vesting	Issuer			75364	09/09/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Martin Wilson 9 Cedarbrook Drive Cranbury NJ 08512	Common	08/13/2026	3493	11810.18
Martin Wilson 9 Cedarbrook Drive Cranbury NJ 08512	Common	08/18/2026	631	2133.66

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	09/11/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Adam Gehring, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Martin Wilson
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)